aTyr Pharma, Inc.

Adial Pharmaceuticals, Inc

Haoxi Health Technology Limited Class A

Psyence Biomedical Ltd. Common Shares

Inhibikase Therapeutics, Inc.

Palisade Bio, Inc.

Medical Properties Trust, Inc.

Cue Biopharma, Inc.

Standard BioTools Inc.

Dilution score: 18/100 (LOW), 24.0 months cash

Short interest: 22.38% of float, squeeze risk: MODERATE

31 PubMed publications found for aTyr , .

Updated trends in the global prevalence and burden of mental disorders, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.

Sex-specific autosomal susceptibility loci in systemic sclerosis: a genome-wide association study.

Global, regional, and national burden of breast cancer among females, 1990-2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023.

Sarcoidosis: a state-of-the-art review.

Differential Effects of Antifibrotic Treatment on Outcome Prediction via Serial Matrix Metalloproteinase-Degraded C-Reactive Protein Neoepitope Levels in Idiopathic Pulmonary Fibrosis.

Dilution score: 25/100 (LOW), 24.4 months cash

Short interest: 20.76% of float, squeeze risk: HIGH

Dilution score: 25/100 (LOW), 27.9 months cash

SW convergence: 41/100 (Bearish Convergence), 1 bullish / 2 bearish signals

30 PubMed publications found for aTyr , .

Design of RESOLVE Lung, a multinational Phase 2, randomized, placebo-controlled trial of the anti-GM-CSF monoclonal antibody namilumab in patients with chronic pulmonary sarcoidosis.

Dilution score: 26/100 (MEDIUM), 27.9 months cash

Dilution score: 21/100 (LOW), 27.9 months cash

Short interest: 20.8% of float, squeeze risk: HIGH

<article class="bts-verified-summary" data-ticker="ATYR">
<p>aTyr Pharma, Inc. Common Stock (ATYR) has no currently recruiting or active clinical trials where it is listed as lead sponsor on ClinicalTrials.gov.</p>
<p>No Form 4 insider filings for ATYR were recorded at the SEC in the past 30 days<sup><a href="#fn-1">[1]</a></sup>.</p>
<section class="sources" data-nosnippet aria-label="Sources"><h3>Sources</h3><ol><li id="fn-1">SEC EDGAR · 0001339970 (2026-04-11) <a href="https://efts.sec.gov/LATEST/search-index?q=%22ATYR%22&amp;forms=4&amp;dateRange=custom&amp;startdt=2026-03-12&amp;enddt=2026-04-11" rel="nofollow noopener noreferrer">↗</a></li></ol></section>
</article>

aTyr Pharma, Inc. Common Stock

SEC EDGAR — 0001339970

aTyr Pharma, Inc. Common Stock (ATYR) — BioTechSigns Verified Summary

aTyr Pharma, Inc. Common Stock (ATYR) has no currently recruiting or active clinical trials where it is listed as lead sponsor on ClinicalTrials.gov.

No Form 4 insider filings for ATYR were recorded at the SEC in the past 30 days[1].

Sources:
[1] SEC EDGAR, 0001339970. Source last updated 2026-04-11, retrieved 2026-04-11.
    https://efts.sec.gov/LATEST/search-index?q=%22ATYR%22&forms=4&dateRange=custom&startdt=2026-03-12&enddt=2026-04-11